» Articles » PMID: 8218997

Natural History of Chronic Hepatitis B Virus Infection: New Light on an Old Story

Overview
Specialty Gastroenterology
Date 1993 Sep 1
PMID 8218997
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic hepatitis B virus (HBV) infection is one of the most common persistent virus infection in man. It causes significant morbidity and mortality, and therefore is important. Extensive studies on clinicopathologic studies and long-term follow up on hepatitis B surface antigen (HBsAg) carriers have largely disclosed the natural history of chronic HBV infection. The infection easily becomes chronic when contracted in early infancy. As high as 90% of babies born to HBV carrier mothers will also become HBsAg carriers. Once chronic infection is established, it is refractory, and HBsAg carriage usually persists for life. However, the chronic infection is not monotonous, it actually evolves from an HBV replicative phase to a non-replicative phase. The host responds differently and with more complexity in different phases. The virus-host interactions, divided into three phases, virus tolerance, virus clearance and residual HBV integrated phases, result in a heterogeneous variety of hepatic lesions. The first two phases occur when HBV is actively replicating, and the last corresponds to the non-replicative phase. The high HBV level (and hence HBV gene products) renders the host's immune system tolerant to the virus, and the infected host does not exert an effort to get rid of the virus. At this stage, the liver is nearly normal, and the host is asymptomatic. However, later in the replicative phase, the HBV replication begins to wane, and the immune tolerance is no longer maintained.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy, Biologicals, Immunosupressants, or Corticosteroids.

Arora A, Anand A, Kumar A, Singh S, Aggarwal R, Dhiman R J Clin Exp Hepatol. 2018; 8(4):403-431.

PMID: 30568345 PMC: 6286881. DOI: 10.1016/j.jceh.2018.06.010.


INASL Position Statements on Prevention, Diagnosis and Management of Hepatitis B Virus Infection in India: The Andaman Statements.

Arora A, Singh S, Kumar A, Saraswat V, Aggarwal R, Bangar M J Clin Exp Hepatol. 2018; 8(1):58-80.

PMID: 29743798 PMC: 5938334. DOI: 10.1016/j.jceh.2017.12.001.


Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy.

Sagnelli E, Stroffolini T, Sagnelli C, Pirisi M, Babudieri S, Colloredo G Infection. 2017; 46(1):93-101.

PMID: 29150796 DOI: 10.1007/s15010-017-1101-5.


Comparison of transient severe motion in gadoxetate disodium and gadopentetate dimeglumine-enhanced MRI: effect of modified breath-holding method.

Song J, Choi E, Park E, Lee J Eur Radiol. 2017; 28(3):1132-1139.

PMID: 28986630 DOI: 10.1007/s00330-017-5070-y.


An HBV-tolerant immunocompetent model that effectively simulates chronic hepatitis B virus infection in mice.

Yuan L, Wang T, Zhang Y, Liu X, Zhang T, Li X Exp Anim. 2016; 65(4):373-382.

PMID: 27264142 PMC: 5111840. DOI: 10.1538/expanim.16-0013.